The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR.
We compared the effect of control genes (CG): total Abelson (total-ABL), beta-2-microglobulin (B2M) and beta-glucuronidase (GUS), recommended in the Europe Against Cancer (EAC) program, on real-time BCR-ABL monitoring in patients with chronic myeloid leukemia (CML). We focused on the stability of CG expressions during therapy and the effect of the CGs on BCR-ABL ability to characterize the disease status and disease prognosis, issues that have not been addressed yet. The results showed B2M as a very convenient CG for BCR-ABL monitoring. On the contrary, the widely used total-ABL was not confirmed as appropriate for normalization of gene expression in CML.
Rulcová
Jana
J
Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Zmeková
Václava
V
Zemanová
Zuzana
Z
Klamová
Hana
H
Moravcová
Jana
J
D000328:Adult; D000368:Aged; D018076:DNA, Complementary / Q000235:genetics; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D015973:Gene Expression Regulation, Leukemic; D005966:Glucuronidase / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D012334:RNA, Neoplasm / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D001613:beta 2-Microglobulin / Q000235:genetics*
D018076:DNA, Complementary; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D001613:beta 2-Microglobulin; D016044:Fusion Proteins, bcr-abl; D016315:Proto-Oncogene Proteins c-abl; D005966:Glucuronidase